Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 20Terminated 7Unknown 4Withdrawn 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Rituximab 16Cyclophosphamide 12fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Vincristine 5Radiotherapy 5Prednisone 5Lenalidomide 5Etoposide 5Doxorubicin 5Cytarabine 5Bendamustine Hydrochloride 5fludarabine 4Whole-Body Irradiation 4Filgrastim 4tazemetostat 3Mycophenolic Acid 3Melphalan 3Carmustine 3umbralisib 2ublituximab 2sargramostim 2parsaclisib 2ofatumumab 2ibritumomab tiuxetan 2duvelisib 2Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Follicular × ibritumomab tiuxetan × Clear all
NCT00310128 2016-02-03

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

AIDS Malignancy Consortium

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related, Lymphoma, Large-Cell, Anaplastic

NCT00319332 2015-04-17

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

GlaxoSmithKline

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡